These findings echoed similar conclusions reported in prior studies, indicating that high expression of the LOX family, particularly LOX and LOXL2, correlated with adverse survival outcomes in breast cancer (especially in ER‐negative or triple‐negative patients) [25, 26, 27, 28, 29, 30], gastric cancer [31, 32, 33, 34], lung cancer [35, 36], colorectal cancer [37, 38], glioma [39] and pancreatic cancer [40, 41]. This evidence concerns the gene LOXL2 and breast carcinoma.